ClinicalTrials.gg
CompletedNCT00105040Updated Mar 2, 2015

A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures

A Phase 2 interventional study of Levetiracetam and Placebo (PB) in Epilepsy, Partial, sponsored by UCB Pharma. Completed at 45 sites in 3 countries. Open to participants aged 4 Years to 16 Years. Per ClinicalTrials.gov, last updated 2015-03-02.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
87
Allocation
Randomized
Ages
4 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 18 studies testing levetiracetam in Epilepsies, Partial — none open to participants now, none under way, none of them phase 3. Levetiracetam · Epilepsies, Partial.

Enrollment
13th of 18
87 · median 173
Started
2004
with 4 others
Phase 2
Only one
of the 18
Registered
1st of 18
by date
Lead sponsor
10 of 18
UCB Pharma

Among the 18 studies testing levetiracetam in Epilepsies, Partial, this one is the 13th largest by enrollment, is one of 5 that started in 2004, is the only one in phase 2, and was the 1st registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

None of the 18 studies testing levetiracetam in Epilepsies, Partial is open now. The open studies under Epilepsies, Partial, anywhere →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 4 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing levetiracetam in Epilepsies, Partial as a file.
02

Study summary

A 12-week Evaluation Period will be used to characterize potential cognitive and neuropsychological effects of LEV (20 - 60 mg/kg/day), as adjunctive treatment in children 4 - 16 years old, inclusive, with refractory partial onset seizures when compared to adjunctive treatment with placebo.

03

Conditions studied

  • Epilepsy, Partial

Keywords

  • Partial onset seizures
  • epilepsy
  • levetiracetam
  • Keppra
  • cognition
  • behavior
  • pediatry
04

Who can participate

Ages eligible
4 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pediatric subjects (4 - 16 years old) diagnosed with partial onset seizures for a minimum of six months prior to Visit 1 experiencing at least two partial onset seizures during the four weeks prior to Visit 1 will be enrolled
  • Subjects should be on a stable regimen of one or a maximum of two other antiepileptic drugs (AEDs) for at least 2 weeks prior to Visit 1
  • Subject must have an Intelligence Quotient (IQ) as assessed during Visit 1 of at least 70
  • Subject and parent/guardian should be fluent in English

Exclusion criteria

Exclusion Criteria:

  • Subject must not have had previous treatment with levetiracetam unless, in the opinion of the investigator, the subject's previous treatment was inadequate in dose or duration to provide an accurate assessment of the therapy, or the effect of levetiracetam was confounded by concomitant medication
  • Subject is receiving benzodiazepines on a routine or chronic basic and is unable to discontinue use four weeks prior to Visit 1
  • Subject has seizures too close together to accurately count
  • Subject has a current psychiatric disorder other than mild to moderate attention deficit, behavior, or learning disorders
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
87 participants (actual)

Study arms

  • Experimental
    Levetiracetam (LEV)

    Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.

    Drug: Levetiracetam

  • Placebo comparator
    Matching Placebo (PBO)

    Oral tablets and oral solution.

    Other: Placebo (PB)

Interventions

  • Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.

    Also known as: Keppra

  • OtherPlacebo (PB)

    Oral tablets and oral solution

06

What researchers measure

Primary outcomes

  1. Change from Baseline in the Leiter International Performance Scale-Revised (Leiter-R) Attention and Memory (AM) Battery's Memory Screen Composite Score from Baseline (Visit 2) to the end of the Evaluation Period (Week 12 or Early Discontinuation Visit)

    The Leiter-R includes two groupings of sub-tests: (1) the Visualization and Reasoning (VR) Battery with 10 sub-tests of nonverbal intellectual ability related to visualization, reasoning, and spatial ability; and (2) the Attention and Memory (AM) Battery with 10 sub-tests of nonverbal attention and memory function. The Examiner Rating Scale has 49 items that describe the child's activity level, attention, impulse control, and other emotional characteristics that may interact with test performance. The focus of the items is on actions, verbalizations, moods and other behaviors of the child. The examiner rates the child using the following scale: 0 = rarely or never; 1 = sometimes; 2 = often; 3 = usually or always.

    Time frame: Baseline (Visit 2) to the end of the Evaluation Period (Week 12 or Early Discontinuation Visit)

Secondary outcomes

  1. Change from Baseline in Wide Range Assessment of Memory and Learning-Second Edition (WRAML-2) General Memory from Baseline to Week 12 or Early Discontinuation Visit (EDV)

    The WRAML-2 is comprised of 2 Verbal, 2 Visual, and 2 Attention-Concentration sub-tests, yielding a Verbal Memory Index, a Visual Memory Index and an Attention-Concentration Index. Together these sub-tests yield a General Memory Index. Scaled and standard scores allow performance comparisons based on age and 4 delayed recall sub-tests include guidelines for determining the level of recall. A composite General Memory Index score will be computed.

    Time frame: Baseline to Week 12 or EDV

  2. Change from Baseline in Wide Range Assessment of Memory and Learning-Second Edition (WRAML-2) Visual Memory Index from Baseline to Week 12 or Early Discontinuation Visit (EDV)

    The WRAML-2 is comprised of 2 Verbal, 2 Visual, and 2 Attention-Concentration sub-tests, yielding a Verbal Memory Index, a Visual Memory Index and an Attention-Concentration Index. Together these sub-tests yield a General Memory Index. Scaled and standard scores allow performance comparisons based on age and 4 delayed recall sub-tests include guidelines for determining the level of recall. A composite General Memory Index score will be computed.

    Time frame: Baseline to Week 12 or EDV

  3. Change from Baseline in Wide Range Assessment of Memory and Learning-Second Edition (WRAML-2) Verbal Memory Index from Baseline to Week 12 or Early Discontinuation Visit (EDV)

    The WRAML-2 is comprised of 2 Verbal, 2 Visual, and 2 Attention-Concentration sub-tests, yielding a Verbal Memory Index, a Visual Memory Index and an Attention-Concentration Index. Together these sub-tests yield a General Memory Index. Scaled and standard scores allow performance comparisons based on age and 4 delayed recall sub-tests include guidelines for determining the level of recall. A composite General Memory Index score will be computed.

    Time frame: Baseline to Week 12 or EDV

  4. Change from Baseline in Wide Range Assessment of Memory and Learning-Second Edition (WRAML-2) Attention/Concentration Index from Baseline to Week 12 or Early Discontinuation Visit (EDV)

    The WRAML-2 is comprised of 2 Verbal, 2 Visual, and 2 Attention-Concentration sub-tests, yielding a Verbal Memory Index, a Visual Memory Index and an Attention-Concentration Index. Together these sub-tests yield a General Memory Index. Scaled and standard scores allow performance comparisons based on age and 4 delayed recall sub-tests include guidelines for determining the level of recall. A composite General Memory Index score will be computed.

    Time frame: Baseline to Week 12 or EDV

07

Study locations

45 sites
  • Birmingham, Alabama, United States
  • Phoenix, Arizona, United States
  • Tucson, Arizona, United States
  • Little Rock, Arkansas, United States
  • La Jolla, California, United States
  • Los Angeles, California, United States
  • Denver, Colorado, United States
  • Washington, District of Columbia, United States
  • Bradenton, Florida, United States
  • Gainesville, Florida, United States
  • Loxahatchee, Florida, United States
  • Miami, Florida, United States
  • Orlando, Florida, United States
  • Tallahassee, Florida, United States
  • Tampa, Florida, United States
  • Atlanta, Georgia, United States
  • Augusta, Georgia, United States
  • Chicago, Illinois, United States
  • Voorhees, New Jersey, United States
  • Buffalo, New York, United States
  • New York, New York, United States
  • Rochester, New York, United States
  • Winston-Salem, North Carolina, United States
  • Cleveland, Ohio, United States
  • Hershey, Pennsylvania, United States
  • Philadelphia, Pennsylvania, United States
  • Pittsburgh, Pennsylvania, United States
  • Charleston, South Carolina, United States
  • Germantown, Tennessee, United States
  • Dallas, Texas, United States
  • Fort Worth, Texas, United States
  • Galveston, Texas, United States
  • Houston, Texas, United States
  • Norfolk, Virginia, United States
  • Richmond, Virginia, United States
  • Seattle, Washington, United States
  • Morgantown, West Virginia, United States
  • Milwaukee, Wisconsin, United States
  • Scarborough, Ontario, Canada
  • Thornhill, Ontario, Canada
  • Toronto, Ontario, Canada
  • Bloemfontein, South Africa
  • Cape Town, South Africa
  • Capitol Park, South Africa
  • Johannesburg, South Africa
08

References and documents

Publications

  • Levisohn PM, Mintz M, Hunter SJ, Yang H, Jones J; N01103 Levetiracetam Study Group. Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial. Epilepsia. 2009 Nov;50(11):2377-89. doi: 10.1111/j.1528-1167.2009.02197.x. Epub 2009 Aug 21. PubMed 19702752 ↗
  • de la Loge C, Hunter SJ, Schiemann J, Yang H. Assessment of behavioral and emotional functioning using standardized instruments in children and adolescents with partial-onset seizures treated with adjunctive levetiracetam in a randomized, placebo-controlled trial. Epilepsy Behav. 2010 Jul;18(3):291-8. doi: 10.1016/j.yebeh.2010.04.017. Epub 2010 May 23. PubMed 20547106 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2004, a primary completion of Mar 2007 and a completion of Mar 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2005
First posted
Mar 4, 2005
Start
Sep 2004
Primary completionActual
Mar 2007
CompletionActual
Mar 2007
Last update
Mar 2, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00105040
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Mar 4, 2005
Start date
Sep 2004
Primary completion
Mar 2007
Completion
Mar 2007
Last update
Mar 2, 2015

Study contacts

UCB Clinical Trial Call Center
study director · UCB Pharma

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion